



Global Reporting Initiative Index

General Standard Disclosures			
General Standard Disclosures	GRI G4 Indicator	Information or Page Number (or Link) Information related to Standard Disclosures required by the 'in accordance' options may already be included in other reports prepared by the organization. In these circumstances, the organization may elect to add a specific reference to where the relevant information can be found.	Indicator Location
Strategy and Analysis			
G4-1	Provide a statement from the most senior decision-maker of the organization (such as CEO, chair, or equivalent senior position) about the relevance of sustainability to the organization and the organization's strategy for addressing sustainability.		Not Applicable
Organizational Profile			
G4-3	Report the name of the organization.	West Pharmaceutical Services, Inc.	2015 SEC Filing 10K: Page 1
G4-4	Report primary brands, products and services	<p>West is a leading manufacturer of packaging and delivery components and systems for injectable drugs and healthcare products. Our products include stoppers and seals for vials, prefillable syringe components and systems, safety and administration systems, advanced injection systems, and contract design and manufacturing services. Our customers include the leading global producers of pharmaceuticals, biologics, medical devices and consumer products.</p> <p>West's business operations are organized into two reportable segments, Packaging Systems and Delivery Systems. Packaging Systems develops, manufactures and sells primary packaging components and systems for injectable drug delivery, including stoppers and seals for vials, closures and other components used in syringe, intravenous and blood collection systems, and prefillable syringe components. Delivery Systems develops, manufactures and sells safety and administration systems, multi-component systems for drug administration, and a variety of custom contract-manufacturing solutions targeted to the healthcare and consumer-products industries. In addition, Delivery Systems is responsible for the continued development and commercialization of our line of proprietary, multi-component systems for injectable drug administration and other healthcare applications. We also maintain global partnerships to share technologies and market products with affiliates in Japan and Mexico.</p>	Company Website
G4-5	Report the location of the organization's headquarters	530 Herman O. West Drive, Exton, PA 19341	2015 SEC Filing 10K: Page 1
G4-6	Report the number of countries where the organization operates, and names of countries where either the organization has significant operations or that are specifically relevant to the sustainability topics covered in the report.	We have significant operations internationally. These locations include: Australia, Brazil, China, Denmark, England, France, Germany, India, Ireland, Israel, Puerto Rico, Serbia, Singapore, and United States.	2015 SEC Filing 10K: Page 16

G4-7	Report the nature of ownership and legal form.	West Pharmaceutical Services, Inc. is a publically traded company on the New York Stock Exchange, Inc. under tick marker symbol WST.	2015 SEC Filing 10K: Page 20
G4-8	Report the markets served.	<p>Packaging Systems customers include most of the major branded pharmaceutical, generic and biopharmaceutical companies in the world. Packaging Systems components and other products are sold to major pharmaceutical, biotechnology and hospital supply/medical device companies, which incorporate them into their products for distribution to the ultimate end-user.</p> <p>Our Delivery Systems segment sells to many of the world's largest pharmaceutical, biopharmaceutical and medical device companies. Delivery Systems components generally are incorporated into our customers' manufacturing lines for further processing or assembly.</p>	2015 SEC Filing 10K: Page 7
G4-9	Report the scale of the organization.	<p>Employees: 7,000</p> <p>Operations: We are a manufacturer of components and systems for the packaging and delivery of injectable drugs as well as components for the pharmaceutical, healthcare and consumer products industries</p> <p>Net Sales: \$1,399 Million</p> <p>Products and Services: Our products include stoppers and seals for vials, prefillable syringe components and systems, components for intravenous and blood collection systems, safety and administration systems, advanced injection systems, and contract design and manufacturing services</p>	2015 SEC Filing 10K: Page 3 & 22
G4-10	Employees	<p>Full-Time Employees (FTE): 7000</p> <p>There is not a substantial portion of employees that are legally recognized as self-employed.</p> <p>Although our Packaging Systems business is not inherently seasonal, sales, labor hours, and operating profit in the second half of the year are typically lower than the first half primarily due to scheduled plant shutdowns in conjunction with our customers' production schedules and the year-end impact of holidays on production. Our Delivery Systems business is not inherently seasonal.</p>	Not Applicable
G4-12	Describe the organization's supply chain.	<p>We use three basic raw materials in the manufacture of our products: elastomers, aluminum and plastic. Elastomers include both natural and synthetic materials. We currently have access to adequate supplies of these raw materials to meet our production needs through agreements with suppliers.</p> <p>We employ a supply-chain management strategy in our business segments, which involves purchasing from integrated suppliers that control their own sources of supply. Due to regulatory control over our production processes, and the cost and time involved in qualifying suppliers, we rely on single-source suppliers for many critical raw materials. We purchase a portion of our raw materials in the open market. This strategy increases the risk that our supply chain may be interrupted in the event of a supplier production problem. These risks are managed, where possible, by selecting suppliers with multiple manufacturing sites, rigorous quality control systems, surplus inventory levels and other methods of maintaining supply in case of an interruption in production.</p>	2015 SEC Filing 10K: Page 6

<p>G4-13</p>	<p>Report any significant changes during the reporting period regarding the organization's size, structure, ownership, or its supply chain.</p>	<p>In 2015, our business operations consisted of two reportable segments, the Pharmaceutical Packaging Systems segment ("Packaging Systems") and the Pharmaceutical Delivery Systems segment ("Delivery Systems"). Beginning in 2016, we changed our organization and reporting structure for our next phase of growth and development, which will result in a change to Proprietary Products and Contract-Manufactured Products as reportable segments. The Proprietary Products reportable segment, which will combine the existing Packaging Systems segment with the proprietary products portion of the existing Delivery Systems segment, will develop commercial, operational, and innovation strategies across our global network, with specific emphasis on product offerings to biologic, generic, and pharmaceutical customers. The Contract-Manufactured Products reportable segment, which will consist of the contract manufacturing portion of the existing Delivery Systems segment, will serve as a fully integrated business focused on the design, manufacture, and automated assembly of complex assemblies for pharmaceutical and medical device customers.</p> <p>The information and discussion included in this section reflects the structure in place as of December 31, 2015.</p> <p>In October 2014, we announced plans to expand our global manufacturing operations to include a new facility in Waterford, Ireland, which will produce packaging components for insulin injector cartridges and other high-value packaging components. Construction began in July 2015.</p>	<p>2015 SEC Filing 10K: Page 4 & 18</p>
<p>G4-14</p>	<p>Report whether and how the precautionary approach or principle is addressed by the organization.</p>	<p>As a company dedicated to producing products to enhance health, West is committed to a healthier environment. West wants to prevent adverse environmental impact through our manufacturing processes and our products themselves. West's policy is to reduce or eliminate the creation of waste at its source, to recycle, and to dispose of any waste responsibly. As part of West's environmental policy, West complies with all applicable environmental laws, permits and approvals.</p> <p>West has a long-standing commitment to environmental responsibility in our products, operations and with the broader community. West's Sustainability Program focuses on reductions in greenhouse gas emissions, waste, energy and water usage, and increased recycling. West employees are expected to support our commitment to the environment by:</p> <ul style="list-style-type: none"> - Integrating sustainability principles into all business processes, planning and decision making; - Identifying waste and inefficiencies; - Engaging in best practice sharing around the globe; - Committing to continuous improvement in West's environmental performance; - Reporting to appropriate Company resources any practice that is harmful to the environment or does not comply with our Company's policies or with governing laws, rules and regulations. 	<p>Code of Business Conduct</p>

<p>G4-15</p>	<p>List externally developed economic, environmental and social charters, principles, or other initiatives to which the organization subscribes or which it endorses.</p>	<p>West Joined PSCI in January of 2014</p>	<p>West Joins PSCI</p>
<p>G4-16</p>	<p>List memberships of associations (such as industry associations) and national or international advocacy organizations.</p>	<p>1. Pharmaceutical Supply Chain Initiative – Treasurer; Audit. Supplier Capability Building and Board of Directors; just membership fees; Strategic 2. RX-360 – No Position: Quality Agreement and Customer Questionnaire work streams: just membership fee: Strategic 3. DCAT – Marketing Committee: Various work streams; Sponsorships and membership fees; Strategic 4. NAM – No position; Sustainability Task Force: Basic membership fee: Informational</p>	<p>Not Applicable</p>
<p>Identified Material Aspects and Boundaries</p>			
<p>G4-17</p>	<p>a. List all entities included in the organization’s consolidated financial statements or equivalent documents. b. Report whether any entity included in the organization’s consolidated financial statements or equivalent documents is not covered by the report.</p>	<p>a. A complete list of all entities included in our consolidated financial statements and equivalent documents can be found at the following link to our 2015 10k SEC filing. b. This report covers our parent company, West Pharmaceutical Services, Inc. and all additional subsidiaries in which West holds a controlling interest.</p>	<p>2015 SEC Filing 10K: Page 17 & 33</p>
<p>G4-18</p>	<p>a. Explain the process for defining the report content and the Aspect Boundaries. b. Explain how the organization has implemented the Reporting Principles for Defining Report Content.</p>	<p>The methodology behind West’s materiality assessment is aligned with our business strategy and guided by GRI’s framework which is the industry standard. To fulfil our materiality assessment a team of key individuals from various business functions were pulled together to engage with stakeholders. The process West uses to conduct its materiality assessment is outlined below:</p> <ol style="list-style-type: none"> 1. Identification of the Aspects as well as their internal or external impacts on our business and stakeholders. 2. Prioritization of the Aspects through discussion, qualitative analysis and quantitative assessment to understand how significant each Aspect is. 3. Validation of each of the Aspects to ensure they reflect the organization’s significant environmental, social, or governance impacts; or substantively influence the assessments and decisions of stakeholders. 	<p>Materiality Assessment Document: Page 3</p>

<p>G4-19</p>	<p>List all the material Aspects identified in the process for defining report content.</p>	<p>Waste Management & Recycling Environmental Management 1. GHG Emissions Management 2. Energy Management 3. Water Management Sustainable R&D 4. Innovation 5. Design for the Environment 6. Product Safety 7. Green Chemistry</p>	<p>Worker Health & Safety Social Issues 8. Harassment of any Kind 9. Diversity & Equal Opportunity 10. Supplier Diversity Philanthropy 11. Corporate Giving 12. Employee Giving 13. Volunteerism Contingency Plan</p>	<p>Legal Compliance 14. REACH 15. Conflict Minerals 16. CA Transparency in SC UK MSA 17. Anti-Corruption 18. Protection of Personal Information 19. Intellectual Property Business Integrity 20. Code of business Conduct 21. Business Partner Code of Conduct</p>	<p>Materiality Assessment Document: Page 4</p>
<p>G4-20</p>	<p>For each material Aspect, report the Aspect Boundary within the organization (see comment)</p>	<p>Internal: 8. Harassment of any Kind 9. Diversity & Equal Opportunity 10. Supplier Diversity 18. Protection of Personal Information 19. Intellectual Property 20. Code of business Conduct</p>	<p>Internal and External: 1. GHG Emissions Management 2. Energy Management 3. Water Management 11. Corporate Giving 12. Employee Giving 13. Volunteerism 14. REACH 21. Business Partner Code of Conduct</p>		<p>Materiality Assessment Document: Page 5</p>
<p>G4-21</p>	<p>For each material aspect, report the Aspect Boundary outside the organization</p>	<p>External: 4. Innovation 5. Design for the Environment 6. Product Safety 7. Green Chemistry 15. Conflict Minerals 16. CA Transparency in SC / UK MSA 17. Anti-Corruption</p>	<p>Internal and External: 1. GHG Emissions Management 2. Energy Management 3. Water Management 11. Corporate Giving 12. Employee Giving 13. Volunteerism 14. REACH 21. Business Partner Code of Conduct</p>		<p>Materiality Assessment Document: Page 5</p>
<p>G4-22</p>	<p>Report the effect of any restatements of information provided in previous reports, and the reasons for such restatements.</p>	<p>This document is West's first reporting following the GRI guidelines</p>			<p>Not Applicable</p>
<p>G4-23</p>	<p>Report significant changes from previous reporting periods in the Scope and Aspect Boundaries.</p>	<p>This document is West's first reporting following the GRI guidelines</p>			<p>Not Applicable</p>

Stakeholder Engagement			
G4-24	Provide a list of stakeholder groups engaged by the organization.	Internal: - Executive Team and Board of Directors - Employees External: - Customers - Suppliers - Investors - Regulatory - Communities - NGO's - Social Followers	Materiality Assessment Document: Page 5
G4-25	Report the basis for identification and selection of stakeholders with whom to engage.	We have identified our stakeholders as those that have interest, expectations and requirements around our business.	Materiality Assessment Document: Page 2
G4-26	Report the organization's approach to stakeholder engagement, including frequency of engagement by type and by stakeholder group, and an indication of whether any of the engagement was undertaken specifically as part of the report preparation process.	We engage with our stakeholders on a day-to-day basis. This engagement may include surveys, focus groups, community panels, corporate advisory panels, written communication, management structures, or other various vehicles for engagement. To complete the materiality assessment a team of key individuals from various functional groups such as, Sales, Marketing, Research and Development, Procurement, Legal, and Philanthropy were pulled together to determine which areas were most important to our organization and stakeholders.	Materiality Assessment Document: Page 2
G4-27	Report key topics and concerns that have been raised through stakeholder engagement, and how the organization has responded to those key topics and concerns, including through its reporting. Report the stakeholder groups that raised each of the key topics and concerns.	In order to meet the expectations and requirements of our stakeholders and keep pace with our business priorities, we engage with our wide array of stakeholders consistently throughout the year. Through our materiality assessment we defined 21 Aspects as the most material to West and our stakeholders. A multifunctional working team engaged with our stakeholders on the importance of each of the topics and their respective relevance to West and our stakeholders.	Materiality Assessment Document: Page 2 & 3
Report Profile			
G4-28	Reporting period (such as fiscal or calendar year) for information provided.	January 1st, 2015 - December 31st, 2015	Not Applicable

G4-29	Date of most recent previous report (if any).	This document is West's first reporting following the GRI guidelines	Not Applicable
G4-30	Reporting cycle.	Q2 Annually	Not Applicable
G4-31	Provide the contact point for questions regarding the report or its contents.	Name: Gary Wilson Email: Gary.Wilson@Westpharma.com Name: Tyler Werner Email: Tyler.Werner@Westpharma.com	Not Applicable
G4-32	a. Report the 'in accordance' option the organization has chosen. b. Report the GRI Content Index for the chosen option (see tables below). c. Report the reference to the External Assurance Report, if the report has been externally assured. GRI recommends the use of external assurance but it is not a requirement to be 'in accordance' with the Guidelines.	a. 'In accordance' option: Core b. General Standard Disclosures and Specific Standard Disclosures c. This report does not contain any external assurance	Not Applicable
G4-33	a. Report the organization's policy and current practice with regard to seeking external assurance for the report. b. If not included in the assurance report accompanying the sustainability report, report the scope and basis of any external assurance provided. c. Report the relationship between the organization and the assurance providers. d. Report whether the highest governance body or senior executives are involved in seeking assurance for the organization's sustainability report.	This report does not contain any form of external assurance.	Not Applicable

Governance					
G4-34	Report the governance structure of the organization, including committees of the highest governance body. Identify any committees responsible for decision-making on economic, environmental and social impacts.	Governance Information can be found on our website			Corporate Governance
Ethics and Integrity					
G4-56	Describe the organization's values, principles, standards and norms of behavior such as codes of conduct and codes of ethics.	<p>Every day West helps to improve the lives of millions of people around the globe. To do so, we hold ourselves to the highest standards of quality, integrity and respect – for our customers and ourselves. Together, we work as one team to provide value to our business partners and to ensure the safe and effective administration of life saving drugs to patients.</p> <p>Those values are at the heart of our Company's good reputation and success. And they are in the hearts of each and every one of us. Our core values of respect and dignity for the individual, integrity, honesty and accountability enable us to meet the demands of our customers, our industry and each other. The Code of Business Conduct reflects these values and establishes the central principles that govern all West employees.</p>			Code of Business Conduct
Specific Standard Disclosures					
DMA and Indicators	GRI G4 Indicator	Page Number (or Link) Information related to Standard Disclosures required by the 'in accordance' options may already be included in other reports prepared by the organization. In these circumstances, the organization may elect to add a specific reference to where the relevant information can be found.	Identified Omission(s) In exceptional cases, if it is not possible to disclose certain required information, identify the information that has been omitted.	I Reason(s) for Omission(s) In exceptional cases, if it is not possible to disclose certain required information, provide the reason for omission.	Indicator Location If any
Category: Economic					
Material Aspect: Economic Performance					
G4-EC1	Direct Economic Value generated and distributed	<p>a. Revenue: \$1,399 MM Operating Cost: \$128.6 MM Dividend Payments: \$32.4 MM Community investment: \$1.51 MM</p> <p>b. A regional and market break down of EVG&D, please use the link provided to access our 10k SEC filing.</p>	Not Applicable	Not Applicable	2015 SEC Filing 10K

Category: Environmental

Material Aspect: Energy					
G4-EN3	Energy consumption within the organization	c. 409,828,499 kWh f. The Climate Registry - 2015 Gen. Reporting Protocol g. https://www.theclimateregistry.org/tools-resources/reporting-protocols/general-reporting-protocol/	a. Report total fuel consumption from non-renewable sources in joules or multiples, including fuel types used. b. Report total fuel consumption from renewable fuel sources in joules or multiples, including fuel types used. d. Report in joules, watt-hours or multiples, the total: Electricity sold, Heating sold and Cooling sold.	a. We do not capture all of the fuel types used b. We do not currently use renewable energy sources d. We do not sell any energy	Not Applicable
G4-EN5	Energy intensity	a. Intensified to Cost of Goods Manufactured (COGM) b. COGM (USD) c. All; Electricity, Heating, Cooling, Steam, and Fuel d. 22% Internal / 78% External	Not Applicable	Not Applicable	Not Applicable
G4-EN6	Reduction of energy consumption	a. 12% Energy reduction from 2011-2015 b. Types of energy include: fuel, electricity, heating, and cooling c. Our chosen baseline year was 2011 with an intensity goal that extends to 2020 to reduce energy by 25%. d. Our methodology is determined through an internal assessment to choose an intensity ratio that best suits the operations of our business.	Not Applicable	Not Applicable	Not Applicable
Material Aspect: Water					
G4-EN8	Total water withdrawal by source	a. 197,232,000 Gallons b. Information on West's water withdrawal may be drawn from water meters, water bills, calculations derived from other available water data or (if neither water meters nor bills or reference data exist) the organization's own estimates.	Not Applicable	Not Applicable	Not Applicable

Material Aspect: Emissions					
G4-EN15	Direct greenhouse gas (GHG) emissions (scope 1)	<p>a. 28,699 Metric Tons CO2</p> <p>b. CO2 (>99%), CH4 (<1%) and N2O (<1%)</p> <p>c. No biogenic CO2 emissions</p> <p>d. Baseline year: 2011 with a 2020 intensity goal to reduce emissions by 20%. 2015 scope 1 emissions: 26,493 Metric Tons CO2</p> <p>e. All scope 1 emissions are derived from invoices that are sent to a GRI certified 3rd party who applies the The Climate Registry - 2015 Gen. Reporting Protocol standards.</p> <p>f. The Climate Registry - 2015 Gen. Reporting Protocol</p> <p>g. Scope 1 emissions are managed by financial control</p>	Not Applicable	Not Applicable	Not Applicable
G4-EN16	Energy indirect greenhouse gas (GHG) emissions (scope 2)	<p>a. 118,243 Metric Tons CO2</p> <p>b. CO2 (>99%), CH4 (<1%) and N2O (<1%)</p> <p>c. Baseline year: 2011 with a 2020 intensity goal to reduce emissions by 20%. 2015 scope 1 emissions: 118,057 Metric Tons CO2</p> <p>d. All scope 2 emissions are derived from invoices that are sent to a GRI certified 3rd party who applies the The Climate Registry - 2015 Gen. Reporting Protocol standards.</p> <p>e. The Climate Registry - 2015 Gen. Reporting Protocol</p> <p>f. Scope 1 emissions are managed by financial control</p>	Not Applicable	Not Applicable	Not Applicable
G4-EN18	Greenhouse gas (GHG) emissions intensity	<p>b. Cost of Goods Manufactured (USD)</p> <p>c. Direct (scope 1) and indirect (scope 2)</p> <p>d. CO2 (>99%), CH4 (<1%) and N2O (<1%)</p>	Not Applicable	Not Applicable	Not Applicable

G4-EN19	Reduction of greenhouse gas (GHG) emissions	<p>a. 16.9% Intensity reduction in Scope 1 and 2 emissions from 2011 to 2015</p> <p>b. CO2 (>99%), CH4 (<1%) and N2O (<1%)</p> <p>c. Baseline year: 2011 with a 2020 intensity goal to reduce emissions by 20%</p> <p>d. All scope 1 & 2 emissions are derived from invoices that are sent to a GRI certified 3rd party who applies the The Climate Registry - 2015 Gen. Reporting Protocol standards.</p> <p>e. Our reductions were primarily a result from an intensity reduction of scope 2 emissions. Scope 1 emissions was also a contributor to an overall reduction but miniscule compared to scope 2 emissions.</p>	Not Applicable	Not Applicable	Not Applicable
Material Aspect: Compliance					
G4-EN29	Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulations	West has not had any significant fines or non-monetary sanctions for non compliance with environmental laws and regulations	Not Applicable	Not Applicable	Not Applicable
Category: Social					
Sub-Category: Labor Practices and Decent Work					
Material Aspect: Employment					
G4-LA2	Benefits provided to full-time employees that are not provided to temporary or part-time employees, by significant locations of operation	<p>a. Full-Time Employee benefits may include:</p> <ul style="list-style-type: none"> - Life insurance - Health care - Disability and invalidity coverage - Parental leave - Retirement provision - Stock ownership <p>b. 'Significant locations of operation' are facilities that fall under our parent company, West Pharmaceutical Services, Inc. and all additional subsidiaries in which West holds a controlling interest.</p>	Not Applicable	Not Applicable	2015 SEC Filing 10K

Material Aspect: Occupational Health and Safety					
G4-LA5	Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs.	a. At West, formal joint management-worker health and safety committees exist and operate at the facility level, regional level, and organizational level. b. 100% of West employees are represented in formal joint management-worker health and safety committees	Not Applicable	Not Applicable	Not Applicable
G4-LA6	Type of injury and rates of injury, occupational diseases, lost days, and absenteeism, and total number of work-related fatalities, by region and by gender	<p>a. Global: Injury Rate (IR): 2.03 Lost Day Rate (LDR): 0.98 Work Related Fatalities: 0</p> <p>Europe: Injury Rate (IR): 2.15 Lost Day Rate (LDR): 2.10 Work Related Fatalities: 0</p> <p>Asia Pacific: Injury Rate (IR): 1.34 Lost Day Rate (LDR): 1.11 Work Related Fatalities: 0</p> <p>Americas: Injury Rate (IR): 2.21 Lost Day Rate (LDR): 0.38 Work Related Fatalities: 0 Contract Manufacturing: Injury Rate (IR): 1.39 Lost Day Rate (LDR): 0.55 Work Related Fatalities: 0</p>	<p>a. Report types of injury, injury rate (IR), occupational diseases rate (ODR), lost day rate (LDR), absentee rate (AR) and work-related fatalities, for the total workforce (that is, total employees plus supervised workers)</p> <p>b. Report types of injury, injury rate (IR), occupational diseases rate (ODR), lost day rate (LDR), absentee rate (AR) and work-related fatalities for independent contractors working on-site to whom the organization is liable for the general safety of the working environment</p>	<p>a. Absentee Rate (AR) are not captured in the scope of health and safety for full-time salaries employees.</p> <p>b. IR, LDR, ODR and AR are not captured by West for independent contractors.</p>	Not Applicable
G4-LA7	Workers with high incidence or high risk of diseases related to their occupation	a. West does not have any workers who are involved in occupational activities that could lead to a high incidence or high risk of any specific diseases	Not Applicable	Not Applicable	Not Applicable
G4-LA8	Health and safety topics covered in formal agreements with trade unions	a. Formal agreements with trade unions do not cover health and safety b. Not Available	Not Applicable	Not Applicable	Not Applicable

Material Aspect: Diversity and Inclusion					
G4-LA12	Composition of governance bodies and breakdown of employees per employee category according to gender, age group, minority group membership, and other indicators of diversity	Executive officers: 18% Women Total Employees: 36% Women	Not Applicable	Not Applicable	Not Applicable
Sub-Category: Society					
Material Aspect: Anti-Corruption					
G4-S04	Communication and training on anti-corruption policies and procedures	a. 100% b. 100% c. 100% d. 100% e. 100%	Not Applicable	Not Applicable	Not Applicable
Material Aspect: Compliance					
G4-S08	Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with laws and regulations	None	Not Applicable	Not Applicable	Not Applicable
Sub-Category: Product Responsibility					
Material Aspect: Customer Health and Safety					
G4-PR2	Total number of incidents of non-compliance with regulations and voluntary codes concerning the health and safety impacts of products and services during their life cycle, by type of outcomes	None	Not Applicable	Not Applicable	Not Applicable
Material Aspect: Product and Service Labeling					
G4-PR4	Total number of incidents of non-compliance with regulations and voluntary codes concerning product and service information and labeling, by type of outcomes	None	Not Applicable	Not Applicable	Not Applicable

Material Aspect: Marketing Communications					
G4-PR7	Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion, and sponsorship, by type of outcomes	None	Not Applicable	Not Applicable	Not Applicable
Material Aspect: Compliance					
G4-PR9	Monetary value of significant fines for non-compliance with laws and regulations concerning the provision and use of products and services	None	Not Applicable	Not Applicable	Not Applicable